Valeant Says Senior Executive's Departure Unrelated to Probe

  • Deb Jorn left for personal reasons, according to Valeant
  • `The optics of the resignation certainly do not look good'

Valeant Pharmaceuticals International Inc. said the departure of Deb Jorn, its head of U.S. dermatology products, wasn’t the result of any action taken by an ad hoc board committee that’s probing the drugmaker’s now-severed relationships with a controversial mail-order pharmacy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.